(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are PAVmed, Outlook Therapeutics, and DouYu.

The three biggest losers today are PAVmed, AMC, and Ontrak.

Winners today

1. PAVmed (PAVMW) – 105.67%

NASDAQ ended the session with PAVmed jumping 105.67% to $0.03 on Monday while NASDAQ jumped 0.11% to $16,396.83.

Moving Average

PAVmed’s worth is way below its 50-day moving average of $0.21 and way under its 200-day moving average of $1.66.

More news about PAVmed.

2. Outlook Therapeutics (OTLK) – 27.43%

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

NASDAQ ended the session with Outlook Therapeutics rising 27.43% to $11.94 on Monday, after three successive sessions in a row of gains. NASDAQ rose 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Outlook Therapeutics has a trailing twelve months EPS of $-4.

Yearly Top and Bottom Value

Outlook Therapeutics’s stock is valued at $11.94 at 17:32 EST, way under its 52-week high of $40.60 and way above its 52-week low of $4.00.

Moving Average

Outlook Therapeutics’s worth is way above its 50-day moving average of $8.18 and way under its 200-day moving average of $14.32.

More news about Outlook Therapeutics.

3. DouYu (DOYU) – 13.66%

DouYu International Holdings Limited, together with its subsidiaries, operates a platform on PC and mobile apps that provides interactive games and entertainment live streaming services in the People's Republic of China. Its platform connects game developers and publishers, professional eSports teams or players and eSports tournament organizers, advertisers, and viewers. The company also sponsors professional players and teams, and organizes eSports tournaments. In addition, it streams other content to include a spectrum of live streaming entertainment options, such as talent shows, music, outdoor, and travel. Further, the company records and offers video clips to allow users to watch replays of selective live streaming content. DouYu International Holdings Limited was founded in 2014 and is headquartered in Wuhan, the People's Republic of China.

NASDAQ ended the session with DouYu jumping 13.66% to $7.49 on Monday, after three consecutive sessions in a row of losses. NASDAQ jumped 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, DouYu has a trailing twelve months EPS of $0.62.

PE Ratio

DouYu has a trailing twelve months price to earnings ratio of 12.08. Meaning, the purchaser of the share is investing $12.08 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.08%.

Volume

Today’s last reported volume for DouYu is 350051 which is 297.34% above its average volume of 88098.

More news about DouYu.

4. Ontrak (OTRKP) – 12.35%

Ontrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to third-party payors in the United States. Its technology-enabled platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages and guides them to and through the care they need. The company's technology enabled OnTrak program provides healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions, such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators, who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was incorporated in 2003 and is headquartered in Henderson, Nevada.

NASDAQ ended the session with Ontrak jumping 12.35% to $0.68 on Monday, after two sequential sessions in a row of gains. NASDAQ jumped 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Ontrak has a trailing twelve months EPS of $-2.843.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -714.32%.

Volume

Today’s last reported volume for Ontrak is 1444 which is 66.57% below its average volume of 4320.

Moving Average

Ontrak’s value is way higher than its 50-day moving average of $0.52 and way higher than its 200-day moving average of $0.51.

More news about Ontrak.

5. OPKO Health (OPK) – 12.15%

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

NASDAQ ended the session with OPKO Health jumping 12.15% to $1.20 on Monday, after two consecutive sessions in a row of gains. NASDAQ jumped 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat positive trend trading session today.

OPKO health (opk) to restructure after asset buyout by labcorpThe latest announcement is expected to enable OPKO Health to strengthen its foothold in the biopharmaceutical space., The assets that will be acquired from OPKO Health currently generate approximately $100 million in annual revenues.

Earnings Per Share

As for profitability, OPKO Health has a trailing twelve months EPS of $-0.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.8%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

OPKO Health’s EBITDA is -31.04.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 350% and a negative 200%, respectively.

More news about OPKO Health.

6. Xenetic Biosciences (XBIO) – 11.41%

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

NASDAQ ended the session with Xenetic Biosciences jumping 11.41% to $4.20 on Monday, following the last session’s downward trend. NASDAQ rose 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-2.71.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.98%.

Yearly Top and Bottom Value

Xenetic Biosciences’s stock is valued at $4.20 at 17:32 EST, way below its 52-week high of $5.97 and way above its 52-week low of $2.55.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Xenetic Biosciences’s EBITDA is 2.8.

Sales Growth

Xenetic Biosciences’s sales growth for the current quarter is 39.9%.

Volatility

Xenetic Biosciences’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.59%, a negative 0.74%, and a positive 3.62%.

Xenetic Biosciences’s highest amplitude of average volatility was 4.39% (last week), 3.85% (last month), and 3.62% (last quarter).

More news about Xenetic Biosciences.

7. Quantum Corporation (QMCO) – 8.2%

Quantum Corporation provides products for storing and managing digital video and unstructured data in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CatDV, an asset management and workflow orchestration platform that provides asset management, automation, and collaboration tools for organization that manages large volumes of digital media; StorNext software systems that enable high-speed ingest, editing, processing, and management of digital video and image datasets; and Scalar tape systems that provide long-term data storage facility to archive and preserve digital content for decades. It also provides DXi backup appliances for backup storage and multi-site disaster recovery; portfolio of products designed for the capture and analysis of video surveillance and security, including video recording servers, as well as hyperconverged storage systems for video surveillance management and recording; and appliances designed for video surveillance analytics and to run various types of access control systems. In addition, the company offers managed services, customer support agreements, software subscriptions, installation, and consulting and training services; and object storage systems for online content repositories, such as media archives, genome sequencing data repositories, and big data lakes. Further, it sells linear tape-open (LTO) tape cartridges, as well as standalone LTO tape drives for small business and desktop use. The company sells its products through a network of distributors, value-added resellers, direct marketing resellers, original equipment manufacturers, and other suppliers, as well as directly to corporate entities and government agencies. Quantum Corporation was founded in 1980 and is headquartered in San Jose, California.

NASDAQ ended the session with Quantum Corporation jumping 8.2% to $0.60 on Monday, following the last session’s upward trend. NASDAQ rose 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Quantum Corporation has a trailing twelve months EPS of $-0.4.

Sales Growth

Quantum Corporation’s sales growth for the current quarter is negative 16.3%.

More news about Quantum Corporation.

8. PowerFleet (PWFL) – 8.1%

PowerFleet, Inc. provides wireless Internet-of-Things asset management solutions in the United States, Israel, and internationally. The company offers real-time intelligence for organizations to capture IoT data from various types of assets with devices and sensors to increase efficiencies, and improve safety and security, as well as increase their profitability in easy-to-understand reports, dashboards, and real-time alerts; and application programming interfaces for additional integrations and development to boost other enterprise management systems and third-party applications. It also provides hosting, maintenance, and support and consulting services; and Software as a Service, including system monitoring, help desk technical support, escalation procedure development, routine diagnostic data analysis, and software updates services. The company offers its products under the PowerFleet, Pointer, and Cellocator brands. It sells its products to commercial and government sectors in manufacturing, automotive manufacturing, wholesale and retail, food and grocery distribution, pharmaceutical and medical distribution, construction, mining, utilities, heavy industry, aerospace and defense, homeland security, and vehicle rental, logistics, shipping, and freight transportation markets, as well as through indirect sales channels, such as original equipment manufacturers, vehicle importers, distributors, and industrial equipment dealers. The company was formerly known as I.D. Systems, Inc. PowerFleet, Inc. was incorporated in 1993 and is headquartered in Woodcliff Lake, New Jersey.

NASDAQ ended the session with PowerFleet rising 8.1% to $5.34 on Monday, after four sequential sessions in a row of gains. NASDAQ rose 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, PowerFleet has a trailing twelve months EPS of $-0.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.68%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 4.2%, now sitting on 133.59M for the twelve trailing months.

Yearly Top and Bottom Value

PowerFleet’s stock is valued at $5.34 at 17:32 EST, under its 52-week high of $5.49 and way higher than its 52-week low of $1.64.

Moving Average

PowerFleet’s value is way above its 50-day moving average of $3.42 and way higher than its 200-day moving average of $2.70.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is a negative 200% and positive 100% for the next.

More news about PowerFleet.

9. Aspen Group (ASPU) – 7.49%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group jumping 7.49% to $0.28 on Monday, after two consecutive sessions in a row of gains. NASDAQ rose 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.95%.

More news about Aspen Group.

10. Pulmatrix (PULM) – 7.36%

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

NASDAQ ended the session with Pulmatrix jumping 7.36% to $1.75 on Monday while NASDAQ jumped 0.11% to $16,396.83.

Earnings Per Share

As for profitability, Pulmatrix has a trailing twelve months EPS of $-4.44.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.18%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 6.4%, now sitting on 6.8M for the twelve trailing months.

Sales Growth

Pulmatrix’s sales growth for the current quarter is 28.9%.

More news about Pulmatrix.

Losers Today

1. PAVmed (PAVM) – -20.59%

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

NASDAQ ended the session with PAVmed sliding 20.59% to $2.14 on Monday, following the last session’s downward trend. NASDAQ rose 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, PAVmed has a trailing twelve months EPS of $-10.5.

Revenue Growth

Year-on-year quarterly revenue growth grew by 836.6%, now sitting on 2.45M for the twelve trailing months.

Sales Growth

PAVmed’s sales growth is 142.2% for the present quarter and 701.2% for the next.

Moving Average

PAVmed’s worth is below its 50-day moving average of $2.24 and way below its 200-day moving average of $3.44.

Yearly Top and Bottom Value

PAVmed’s stock is valued at $2.14 at 17:32 EST, way below its 52-week high of $7.97 and way above its 52-week low of $1.60.

More news about PAVmed.

2. AMC (AMC) – -15.59%

AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. It owns, operates, or has interests in theatres in the United States and Europe. The company was founded in 1920 and is headquartered in Leawood, Kansas.

NYSE ended the session with AMC dropping 15.59% to $3.14 on Monday, following the last session’s downward trend. NYSE dropped 0.53% to $18,216.19, after two sequential sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, AMC has a trailing twelve months EPS of $-2.1.

Volatility

AMC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.51%, a negative 0.99%, and a positive 3.62%.

AMC’s highest amplitude of average volatility was 7.93% (last week), 2.93% (last month), and 3.62% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.5%, now sitting on 4.81B for the twelve trailing months.

Yearly Top and Bottom Value

AMC’s stock is valued at $3.14 at 17:32 EST, way below its 52-week low of $3.59.

More news about AMC.

3. Ontrak (OTRK) – -14.86%

Ontrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to third-party payors in the United States. Its technology-enabled platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages and guides them to and through the care they need. The company's technology enabled OnTrak program provides healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions, such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators, who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was incorporated in 2003 and is headquartered in Henderson, Nevada.

NASDAQ ended the session with Ontrak sliding 14.86% to $0.51 on Monday while NASDAQ jumped 0.11% to $16,396.83.

Earnings Per Share

As for profitability, Ontrak has a trailing twelve months EPS of $-8.03.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -714.32%.

Moving Average

Ontrak’s value is way higher than its 50-day moving average of $0.23 and way below its 200-day moving average of $0.95.

More news about Ontrak.

4. Canopy Growth (CGC) – -12.75%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth falling 12.75% to $7.53 on Monday while NASDAQ jumped 0.11% to $16,396.83.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-15.67.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -121.56%.

Sales Growth

Canopy Growth’s sales growth is negative 17.2% for the ongoing quarter and negative 17.7% for the next.

Volatility

Canopy Growth’s last week, last month’s, and last quarter’s current intraday variation average was 12.68%, 6.18%, and 6.50%.

Canopy Growth’s highest amplitude of average volatility was 19.79% (last week), 11.86% (last month), and 6.50% (last quarter).

More news about Canopy Growth.

5. PAVmed (PAVMZ) – -12.25%

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

NASDAQ ended the session with PAVmed dropping 12.25% to $0.04 on Monday, after five sequential sessions in a row of losses. NASDAQ rose 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat up trend trading session today.

More news about PAVmed.

6. Polar Power (POLA) – -11.89%

Polar Power, Inc. designs, manufactures, and sells direct current (DC) power generators, renewable energy, and cooling systems in the United States and internationally. The company offers DC base power systems, DC hybrid power systems, DC solar hybrid power systems, and mobile power systems. Its DC power systems are available in diesel, natural gas, LPG/propane, and renewable fuel formats. The company serves customers in the telecommunications, military, commercial, industrial, and marine markets. It sells its products through a direct sales force, and a network of independent service providers and dealers. The company was formerly known as Polar Products, Inc. and changed its name to Polar Power, Inc. in October 1991. Polar Power, Inc. was incorporated in 1979 and is based in Gardena, California.

NASDAQ ended the session with Polar Power falling 11.89% to $0.56 on Monday while NASDAQ rose 0.11% to $16,396.83.

Earnings Per Share

As for profitability, Polar Power has a trailing twelve months EPS of $-0.36.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -27.61%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 12%, now sitting on 18.05M for the twelve trailing months.

More news about Polar Power.

7. Atrion (ATRI) – -11.81%

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

NASDAQ ended the session with Atrion falling 11.81% to $408.80 on Monday, after four consecutive sessions in a row of gains. NASDAQ rose 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Atrion has a trailing twelve months EPS of $11.01.

PE Ratio

Atrion has a trailing twelve months price to earnings ratio of 37.13. Meaning, the purchaser of the share is investing $37.13 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.05%.

Volume

Today’s last reported volume for Atrion is 34830 which is 157.69% above its average volume of 13516.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Mar 14, 2024, the estimated forward annual dividend rate is 8.8 and the estimated forward annual dividend yield is 2.01%.

Moving Average

Atrion’s value is way higher than its 50-day moving average of $359.05 and below its 200-day moving average of $425.57.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Atrion’s stock is considered to be oversold (<=20).

More news about Atrion.

8. Rumble (RUM) – -10.4%

Rumble Inc. operates video sharing platforms in the United States, Canada, and internationally. The company operates rumble.com, a platform where users can subscribe to channels to stay in touch with creators, and access video on-demand (VOD) and live content streamed by creators. It also operates locals.com, a subscription platform for creators and subscribers to engage through VOD, podcasts, live chat, polls, and community discussions; and Rumble Advertising Center (RAC), an online advertising management exchange. The company was founded in 2013 and is headquartered in Longboat Key, Florida.

NASDAQ ended the session with Rumble sliding 10.4% to $7.24 on Monday while NASDAQ rose 0.11% to $16,396.83.

Earnings Per Share

As for profitability, Rumble has a trailing twelve months EPS of $-0.58.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.68%.

Volume

Today’s last reported volume for Rumble is 7281900 which is 6.57% above its average volume of 6832600.

Moving Average

Rumble’s worth is way higher than its 50-day moving average of $5.77 and above its 200-day moving average of $6.69.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Rumble’s EBITDA is -28.51.

More news about Rumble.

9. Walgreens Boots (WBA) – -9.91%

Walgreens Boots Alliance, Inc. operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise. The International segment offers sale of prescription drugs and health and wellness, beauty, personal care, and other consumer products outside the United States; and operates pharmacy-led health and beauty retail businesses under the Boots brand stores in the United Kingdom, the Republic of Ireland, and Thailand, as well as the Benavides brand in Mexico and the Ahumada brand in Chile. The U.S. Healthcare segment provides VillageMD, a national provider of value-based care with primary, multi-specialty, and urgent care providers serving patients in traditional clinic settings, in patients' homes and online appointments; Shields, a specialty pharmacy integrator and accelerator for hospitals; and CareCentrix, a participant in the post-acute and home care management sectors. Walgreens Boots Alliance, Inc. was founded in 1909 and is headquartered in Deerfield, Illinois.

NASDAQ ended the session with Walgreens Boots sliding 9.91% to $19.54 on Monday while NASDAQ rose 0.11% to $16,396.83.

Earnings Per Share

As for profitability, Walgreens Boots has a trailing twelve months EPS of $0.66.

PE Ratio

Walgreens Boots has a trailing twelve months price to earnings ratio of 29.61. Meaning, the purchaser of the share is investing $29.61 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.04%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Walgreens Boots’s EBITDA is 140.02.

Yearly Top and Bottom Value

Walgreens Boots’s stock is valued at $19.54 at 17:32 EST, below its 52-week low of $19.68.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Feb 16, 2024, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 4.73%.

More news about Walgreens Boots.

10. ShiftPixy (PIXY) – -9.28%

ShiftPixy, Inc., together with its subsidiaries, provides staffing solutions in the United States. It offers employment administrative services, such as payroll processing, human resources consulting, and workers' compensation administration and coverage. The Company also operates human resources information systems platform to assist in customer acquisition for the onboarding of new clients into the company's closed proprietary operating and processing information system. It primarily serves restaurant and hospitality service industries. The company was incorporated in 2015 and is headquartered in Miami, Florida.

NASDAQ ended the session with ShiftPixy dropping 9.28% to $2.64 on Monday, after five consecutive sessions in a row of losses. NASDAQ jumped 0.11% to $16,396.83, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, ShiftPixy has a trailing twelve months EPS of $-569.18.

Yearly Top and Bottom Value

ShiftPixy’s stock is valued at $2.64 at 17:32 EST, way under its 52-week high of $113.04 and above its 52-week low of $2.57.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ShiftPixy’s EBITDA is -6.13.

Sales Growth

ShiftPixy’s sales growth is negative 30.9% for the present quarter and 0.3% for the next.

More news about ShiftPixy.

Stay up to date with our winners and losers daily report